BioProtein/Q-One ink safety deal

24 March 2003 00:00  [Source: ICB]

BioProtein Technologies, a Paris, France-based biotechnology firm specialising in the production of therapeutic proteins in the milk of transgenic rabbits, has signed to use Glasgow, UK-based Q-One Biotech's biosafety testing and process validation services.

The French company says the deal ensures the safety of the synthesised protein of interest, even though no contaminants transmissible to humans, including prion disease, have been detected in rabbit milk so far.

BioProtein's agreement with Q-One Biotech comes on top of a deal struck last year with Eurogentec for protein purification. 'This agreement enables us to offer our customers a complete solution for their biomanufacturing needs, from the gene to isolated and purified proteins, in compliance with good manufacturing practice standards,' says, BioProtein's chief executive officer Marc Le Bozec.

The transgenic rabbit is seen as an attractive model. Complex proteins such as monoclonal antibodies, plasma proteins and hormones can be produced rapidly in quantities sufficient for clinical studies. Following successful clinical trials, production can be increased to 10kg/year based on 400 lactating rabbits.

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly